

Medizinische Fakultät







TRANSPLANTATIONSZENTRUM

UNIVERSITÄRES LEBERTUMORZENTRUM LEIPZIG

> RANSPLANTATI ZENTRUM LEIPZIG



Thomas Berg

Clinic and Polyclinic for Gastroenterology, Hepatology, Infectiology and Pneumology

University Clinic Leipzig



Guidance for design and endpoints of clinical trials in chronic hepatitis B Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference

	Sterilizing 'cure'	Idealistic functional 'cure'	Realistic functional 'cure'	Attainable Partial functional 'cure'
Clinical scenario	Never infected	Recovery after acute HBV	Chronic HBV with HBsAg loss	Inactive carrier off treatment
HBsAg	Negative	Negative	Negative	Positive
Anti-HBs	Negative/Positive	Positive	Positive/negative	Negative
HBeAg	Negative	Negative	Negative	Negative
Serum HBV DNA	Not detected	Not detected	Not detected	Low level or not de- tected
Hepatic cccDNA,	Not detected	Detected	Detected	Detected
transcription	Not active	Not active	Not active	Low level
Integrated HBV DNA	Not detected	Detected?	Detected	Detected
Liver disease	None	None	Inactive, fibrosis re- gress over time	Inactive
Risk of HCC	Not increased	Not increased	Declines with time	Risk lower vs. active hepatitis

Cornberg M et al. J Hepatol 2019, epub



EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection $\stackrel{\mathcale}{\sim}$


European Association for the Study of the Liver*

HBsAg loss, with or without anti-HBs seroconversion, is an optimal endpoint, as it indicates profound suppression of HBV replication and viral protein expression

(Evidence level II-1, grade of recommendation 1)

EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67:370

Treatment indication in chronic HBV infection – The Phase matters



Charre C et al. Antiviral Res 2019; 169: 104553


Why we are aiming for HBsAg loss if HBsAg per se is not an indicator to start antiviral treatment?

EASL CPG - Why aiming for HBsAg loss?

- As chronic HBV infection cannot be completely eradicated due to the persistence of cccDNA and integrated HBV DNA, it remains unclear whether HBsAg loss adds to the prevention of the long-term complications of chronic HBV infection beyond what can be achieved by the suppression of HBV DNA replication alone
- HCC may still develop even after spontaneous HBsAg loss (annual rate approximately 0.55%)
- The risk, however, is lower if HBsAg loss is achieved at a younger age and/or in the absence of significant fibrosis


Do we need to achieve HBsAg loss fully prevent any adverse outcome?

HBsAg loss further reduces HCC risk after complete viral suppression with nucleos(t)ide analogues




Yip T C-F et al. J Hepatol 2019; 70: 361

Incidence of hepatic events in NA-treated patients according to level of viral suppression and HBsAg loss




Yip T C-F et al. J Hepatol 2019; 70: 361

Incidence of liver-related mortality in NA-treated patients according to level of viral suppression and HBsAg loss



Yip T C-F et al. J Hepatol 2019; 70: 361

HBsAg a valid endpoint for new antiviral compounds?



Coffin CS et al. Gastroenterology 2019; (Epub)

Guidance for design and endpoints of clinical trials in chronic hepatitis B Aiming for attainable functional "cure"?


	Sterilizing 'cure'	Idealistic functional 'cure'	Realistic functional 'cure'	Attainable Partial functional 'cure'
Clinical scenario				Inactive carrier off treatment
HBsAg				Positive
Anti-HBs				Negative
HBeAg				Negative
Serum HBV DNA	-			Low level or not de- tected
Hepatic cccDNA, transcription				Detected Low level
Integrated HBV DNA				Detected
Liver disease				Inactive
Risk of HCC		1		Risk lower vs. active hepatitis

Cornberg M et al. J Hepatol 2019, epub


Guidance for design and endpoints of clinical trials in chronic hepatitis B Aiming for attainable functional "cure"?

	Sterilizing 'cure'	Idealistic functional 'cure'	Realistic functional 'cure'	Attainable Partial functional 'cure'
Clinical scenario				Inactive carrier off treatment
HBsAg				Positive
Anti-HBs		ility of the res		Negative
HBeAg		ase reactivationg-term HCC		Negative
Serum HBV DNA		epatic manife		Low level or not de- tected
Hepatic cccDNA, transcription	Lon	g-term monito	oring?	Detected Low level
Integrated HBV DNA				Detected
Liver disease	00			Inactive
Risk of HCC		1		Risk lower vs. active hepatitis

Phase transition in HBeAg negative infection (carriers) according to baseline HBV DNA and ALT levels



Time since baseline (weeks)




ALT category over time

Time since baseline (weeks)

Zhou K et al. Am J Gastroenterol 2019 Oct 24 (Epub

Phase transition in HBeAg negative infection (carriers) according to baseline HBV DNA levels



Zhou K et al. Am J Gastroenterol 2019 Oct 24 (Epub


HBsAg – a disease progression marker? Does the level matters?

HBsAg quantification – a biomarker to predict disease progression in patients with low baseline viral load (< 2000 IU/mL)

Reactivation of HBeAg negative hepatitis Cumulative incidence of HBeAg-negative hepatitis (%) 40-HBsAg level (IU/ml) <1000 30 ---->1000 P = .00420 10 20 16 18 0 8 10 12 Years of follow-up

Number at risk


Serum	HBSAg	levels	at bas	seline	(IU/mI)									
<1000	585	551	536	521	503	454	357	265	146	90	58			
≧1000	483	460	435	410	394	350	288	210	132	100	57			



Cirrhosis development

Tseng TC et al. *Hepatology* 2013;57:441-450

HCC risk stratification in HBeAg-negative HBV infection by HBV DNA and HBsAg levels




Tseng TC et al. JID 2013:208; 584-593

Guidance for design and endpoints of clinical trials in chronic hepatitis B When aiming for attainable functional "cure" – do we need new biomarkers?

	Sterilizing 'cure'	Idealistic functional 'cure'	Realistic functional 'cure'	Attainable Partial functional 'cure'
Clinical scenario				Inactive carrier off treatment
HBsAg				Positive
Anti-HBs	New	HBV bioma	arkers	Negative
HBeAg		ney helpful for		Negative
Serum HBV DNA		characterisati ty of the infect		Low level or not de- tected
Hepatic cccDNA, transcription		ting the risk of		Detected Low level
Integrated HBV DNA		outcomes?		Detected
Liver disease				Inactive
Risk of HCC				Risk lower vs. active hepatitis


Novel biomarkers for intrahepatic hepatitis B activity



Charre C, et al. Antiviral Res 2019;169:194553

HBcrAg


Hepatitis B core-related antigen (HBcrAg) a biomarker to predict transcriptional acitivity



Not influenced by translation of integrated sequences


Testoni et al. J Hepatol 2019; 70(4):615-625

HBcrAg levels across phases of chronic hepatitis B




Maasoumy B et al. Clin Microbiol Infect 2015

HBcrAg levels according to liver injury markers




Testoni et al. J Hepatol 2019; 70(4):615-625

Correlation between serum HBcrAg levels and HCC incidence




Tseng T-C et al. Gastroenterology 2019; S0016-5085(19)41248-1 (Epub)

Correlation between serum HBcrAg levels and HCC incidence




Tseng T-C et al. Gastroenterology 2019; S0016-5085(19)41248-1 (Epub)

HBV life cycle – HBV RNA



Cornberg M et al. J Hepatol 2016, in press

Serum HBV pgRNA as a clinical marker for cccDNA activity




Humanized mouse model infected with HBeAg-positive wild-type HBV

Giersch K et al. J Hepatol 2017; 66: 454

Serum HBV RNA - a disease activity marker?


Quantitative serum HBV RNA levels at different phases of the chronic HBV infection



The upper and lower end of the bar features the 75- and 25-percentile. The mark inside the bar indicates the median. Significant results are given with significance level in the figure. The proportion of positive samples are indicated among the bars.

Krauel et al. (2016) 32nd annual Meeting of the German Association of the Study of the Liver, GASL

Association between serum and intrahepatic HBV RNA levels and liver histopathology in patients under entecavir treatment




A serum HBV-RNA level cut-off of 2.45 log₁₀ copies/mL had the highest accuracy for distinguishing mild (score <2) from severe liver histopathology

Wang J et al. J Hepatol 2018; 68: 16-24


Serum HBV RNA for predicting treatment response?

Kinetics of HBV serum markers during 48 weeks of entecavir therapy




Wang J et al. J Hepatol 2018; 68:16-24

Effect of NA treatment on serum HBV nucleic acids kinetics




HBsAg components

Potential biomarkers for assessing endpoints – HBsAg components



Modified according to Cornberg M et al. J Hepatol 2016, August 17 epub

Low-level of large and middle HBsAg protein better describe inactive infection as compared to total HBsAg




Pfefferkorn M et al. Gut 2017;0:1-9

EASL Clinical Practice Guideline - Why aiming for HBsAg loss?

• The main advantage of HBsAg loss is that it allows a safe discontinuation of antiviral therapy


New biomarkers helpful in predicting outcome after stopping a finite course of HBV treatment?

NA discontinuation frequently results in virologic and biochemical flares that runs through different phases



TIME

The markers of HBV transcriptional activity-HBcrAg and pgHBV RNA during antiviral therapy with nucleos(t)ide analogue help to predict optimal timing of therapy withdrawal




Carey I et al. J Hepatol 2019;70:e33-e34

Association of HBV RNA (pgRNA virion levels) and viral rebound after discontinuation of NUCs

HBV RNA	Viral rebound (n)	No viral rebound (n)	Total (n)	*p value
Positive	21	0	21	
Below the LoQ	3	9	12	0.001
Total (n)	24	9	33	


*Chi-Square test; n, number of CHB patients.

End-of-treatment HBV RNA levels predict the risk of relapse after stopping NA in HBeAg positive patients with seroconversion



Fan R et al. Clin Gastroenterol Hepatol 2019; S1542-3565(19)30790-6 (Epub)

End-of-treatment HBV RNA levels predict the risk of relapse after stopping NA in HBeAg pos. patients with seroconversion




Fan R et al. Clin Gastroenterol Hepatol 2019; S1542-3565(19)30790-6 (Epub)

Clinical utility of quantitative anti-HBc levels

- Anti-HBc levels are higher in HBsAg-positive patients as compared to those being anti-HBs-positive (but anti-HBc affinity was lower in chronic infection than during recovery)¹
- Low anti-HBc levels are associated with HBsAg seroclearance (cut-off < 3log)²
- Serum levels of anti-HBc correlate with cccDNA positivity in OBI³
- Anti-HBc levels (cut-off ≥ 6.41 IU/ml) were significantly associated with high risk of HBV reactivation during immunosuppressive therapy⁴


¹Han et al. J Clin Virol. 2011;52(4):295-9 ²Hu et al. Clin Gastroenterol Hepatol. 2018 [Epub ahead of print] ³Caviglia et al. J Hepatol. 2018;69(2):301-307 ⁴Yang et al. J Hepatol. 2018 Aug;69(2):286-292.

Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy




Chi H et al. Clin Gastroenterol Hepatol 2019;17(01):182-191.e1

Classification of HBV-cure with new biomarkers




Charre C et al. Antiviral Res 2019; 169: 104553

Classification of HBV-cure with new biomarkers




Modified according to Charre C et al. Antiviral Res 2019; 169: 104553

Chance for transition into a true functional or even complete cure stage after having achieved a partial functional cure?




Modified according to Charre C et al. Antiviral Res 2019; 169: 104553

Immunotherapeutic augmentation of therapeutic vaccination




Maini MK and Pallett LJ. Lancet Gastroenterol Hepatol 2018; 3: 192–202

TLR7-Agonist Vesatolimod to Treat Chronic Hepatitis B (Phase-II-Study)



Clear-cut doise-dependent induction of ISG15 expression (ISG15-mRNA, fold changes) under TLR7-stimuation

TLR7-Agonist Vesatolimod to Treat Chronic Hepatitis B (Phase-II-Study)




Clear-cut doise-dependent induction of ISG15 expression (ISG15-mRNA, fold changes) under TLR7-stimuation

But

ISG15 induction not associated with HBsAg decline at week 24

Janssen, HLA et al., J. Hepatol. 2018; 68: 431-440


Anti-PD1 (immune checkpoint) blockade with nivolumab w/wo therapeutic vaccine in virally suppressed paitents



Gane E et al. J Hepatol 2019, epub


Inzidenz der HBsAg Serumclearance

Yeo YH et al. Gastroenterology 2019;156(3):635-646



- Composite marker comprises HBcAg, HBeAg and a 22kDa truncated core-related protein (p22cr)
- Available since 2014 fully automated quantitative assay (Lumipulse)
- Not influenced by translation of integrated sequences
- Surrogate marker for cccDNA and its transcriptional activity
- Sensitivity problems (3log)


HBV replication cycle and main targets of viral therapies



Martinez M et al. J Viral Hepatol 2019; doi:10.1111/jvh.13090

Augmenting HBV-specific CD4 T cells - it takes two to tango


Functionally augmented HBV-specific CD4 T cells were observed only when combining OX40 stimulation and PD-L1 blockade



- The HBV-specific CD4 T cells predominantly target the polymerase and core proteins.
- Combined OX40 stimulation and PD-L1 blockade functionally augment HBV-specific CD4 T cells.


Jacobi FJ et al. J Hepatol 2019; 70: 1103

Does HBsAg positive ",cure" of the disease and disease associatedn outcomes exist? How to best define HBsAg positive cure of active infection



Charre C et al. Antiviral Res 2019; 169: 104553


HBV-specific T cell responses after stopping NA



- Discontinuation of NA therapy leads to higher HBsAg loss rates in HBeAg-negative CHB patients.
- T cells from patients with subsequent HBsAg loss show a less exhausted phenotype.
- These T cells also express higher levels of activation and proliferation markers at week 12 after discontinuation of therapy.
- Relapse of active HBV replication may trigger immunological environment that enhances responsiveness of HBV-specific T cells *in vitro*.

Secreted factors of hepatitis B virus


Secreted particles and proteins considered by the measurements of HBcrAg versus HBsAg



Hepatitis B Virus DNA-negative Dane particles containing a 22-kDa precore protein (exceeding Dane particles by ~ 100 fold)


> Kimura T et al. JBC 2005; 280: 21713; Luckenbaugh L et al. J Viral Hepat 2015; 22: 561 Figure modified according to Tanaka E and Matsumoto A. Hepatol Res 2014; 44: 1-8

Possible restoration of HBV specific CD8+ T-cell function




Lang J et al. Hepatology International (2019) 13:113–124

HBV infection = A fibrotic liver disease




HBV infection = A fibrotic liver disease




5 years after start of therapy

HBV infection = A fibrotic liver disease





HBV infection = An oncogenic disease


HBV infection = A chronic liver disease



Risk group	Minimal (Reference)		Medium		Medium high		High	
HBV DNA	<2000	2000-	<2000	2000-	2000-	20 000-	≥200 000	
(IU/mL)	<2000	19 999	<2000	19 999	19 999	199 999	≥200 000	
HBsAg (IU/mL)	<1000	<100	≧1000	100- 999	≧1000	I	Ι	
Patient number (%)	662 (30.6)		674 (31.1)		501 (23.1)		328 (15.2)	







Does HBsAg positive "cure" of the disease and diseas associaten outcomes exists? How to best define HBsAg positive cure of active infection

HBV particles detected in serum and liver of HBV-infected patients at the various endpoints of


HBV cure

Pre-therapy		Th				
	Partial cure First months Short-term Long-term			Functional cure	Complete cure	Sterilizing cure
Serum	00000 0000000000000 000000000000000000	0 0000000 0000000000000000000000000000	0 8998 (2009) (2009) (30 8998 (2009) (300) (30)		1 1 1 1 1 1 1 1 1 1 1 1 1 1	Current limit of detection
100001 100001 F00001	100001 100001 100001 100001 100001 100001	100001 100001 100001 100001 100001 100001	000001 000001 000001 000001 000001	100003 100003 100003 100003		
XX	$ \times \times$	$\times \times$	\propto	$x \propto$	$ \times \times$	1

Complete virions RNA virions Subviral particles WWW cccDNA 🔀 Integrated DNA

Buti M and Riveiro-Barciela M et al. Semin Liver Dis 2019; Dec 5


Chance for transition into a true functional or even complete cure stage after having achieved a partial cure?



biomarkers


Modified according to Charre C et al. Antiviral Res 2019; 169: 104553

Chance for transition into a true functional or even complete cure stage after having achieved a partial cure?




Modified according to Charre C et al. Antiviral Res 2019; 169: 104553

Potential biomarkers for assessing endpoints




Modified according to Cornberg M et al. J Hepatol 2016, August 17 epub

HBV life cycle – HBV RNA



Cornberg M et al. J Hepatol 2016, in press

Potential biomarkers for assessing endpoints



Modified according to Cornberg M et al. J Hepatol 2016, August 17 epub

Clinical utility of quantitative anti-HBc levels

- Anti-HBc levels are higher in HBsAg-positive patients as compared to those being anti-HBs-positive (but anti-HBc affinity was lower in chronic infection than during recovery)¹
- Low anti-HBc levels are associated with HBsAg seroclearance (cut-off < 3log)²
- Serum levels of anti-HBc correlate with cccDNA positivity in OBI³
- Anti-HBc levels (cut-off ≥ 6.41 IU/ml) were significantly associated with high risk of HBV reactivation during immunosuppressive therapy⁴

¹Han et al. J Clin Virol. 2011;52(4):295-9 ²Hu et al. Clin Gastroenterol Hepatol. 2018 [Epub ahead of print] ³Caviglia et al. J Hepatol. 2018;69(2):301-307 ⁴Yang et al. J Hepatol. 2018 Aug;69(2):286-292.

Why aiming for HBsAg loss

- The loss of HBsAg is regarded as the optimal treatment endpoint, termed 'functional cure', but it is only rarely achieved with our current antiviral armamentarium.
- Spontaneous HBsAg seroreversion with reactivation of the inflammatory liver process after HBsAg loss is rare and may occur in patients with a significant impairment of their immune function
- The main advantage of HBsAg loss is that it allows a safe discontinuation of antiviral therapy.

Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy

• Clinical relapse occurred in 39 patients (in 46% of patients at year 4 after discontinuation). High level of anti-HBc at the end of treatment (hazard ratio [HR], 0.31 per log IU/mL; P = .002) and low level of HB surface antigen (HBsAg) at the end of treatment (HR, 1.71 per log IU/ mL; P = .032) were associated with a reduced risk of clinical relapse after adjusting for age, start of nucleos(t)ide analogue therapy, HBeAg-status, and consolidation therapy duration. At year 4, 21% of patients with anti-HBc levels at the end of treatment ≥1000 IU/mL developed a clinical relapse compared to 85% of patients with levels <100 IU/mL (P < .001).